ACW December 2025 quarterly activity report & Appendix 4C
Filed with ASX · · 9 pages · English
Sydney, 30 January 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce the release of its quarterly activity report and Appendix 4C f or the three-month period ended 31 December 2025. Highlights and key events: Pivotal XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial – final, 247th participant randomized in December 2025 and positive Interim Analysis outcome January 2
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Continuation of Trading Halt
- ACW positive XanaMIA Interim Analysis outcome
- Trading Halt
- Actinogen secures $4.3m of non-dilutive R&D tax funding
- Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
Later from Actinogen Medical
- ACW secures funding beyond XanaMIA AD trial final results
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW receives further $1.9m FY2025 R&D rebate from ATO
- Actinogen HY2025 financial report and Appendix 4D
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical